Actinogen Medical is a biotechnology company based in Sydney, Australia, developing therapies targeting cognitive impairment associated with various neurological and metabolic diseases. Its primary focus is Xanamem, an oral medication designed to block cortisol production in the brain, currently in Phase II clinical trials for Alzheimer's disease.
Corticrine operates as a pharmaceutical company that develops new therapies for Alzheimer’s dementia.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.